Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colistin + ofloxacin is an antibiotic combination therapy that combines two different classes of antibiotics. Colistin (polymyxin E) is a polymyxin antibiotic that disrupts bacterial cell membranes through a detergent-like mechanism, primarily effective against Gram-negative bacteria including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Ofloxacin is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase, preventing bacterial DNA replication. This combination may be used to treat multidrug-resistant bacterial infections where single antibiotic therapy is insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colistin + ofloxacin.